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Invasive fungal infections continue to increase as at-risk populations expand. The high associated morbidity and mortality with
fungal diseases mandate the continued investigation of novel antifungal agents and diagnostic strategies that include surrogate biomarkers. Biologic markers of disease are useful prognostic indicators during clinical care, and their use in place of traditional survival end points may allow for more rapid conduct of clinical trials requiring fewer participants, decreased trial expense, and limited
need for long-term follow-up. A number of fungal biomarkers have been developed and extensively evaluated in prospective clinical
trials and small series. We examine the evidence for these surrogate biomarkers in this review and provide recommendations for
clinicians and regulatory authorities.
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The use of surrogate end points through the use of indirect
markers known as biomarkers has the potential to replace clinical end points in large-scale licensing therapeutic trials and to
provide additional prognostic information when used during
routine clinical care. Use of biomarkers can avoid the delay of
days to weeks for fungal growth in blood or tissue and may obviate the need for invasive diagnostic procedures. To be useful
as surrogate end points, however, there must be evidence that
these biomarkers correlate with clinically meaningful outcomes. Substantial evidence has been generated pertaining to
the use of fungal biomarkers over the last decade. We review the
available evidence on the use of fungal biomarkers as surrogate
end points in this manuscript.

CRYPTOCOCCOSIS

Surrogate biomarkers for cryptococcosis can be used for diagnosis, prognosis, and treatment decisions. Standard diagnostics
are India ink microscopy, cryptococcal antigen (CrAg), and
culture [1]. Culture and microscopy techniques date to 1894
[2] and are still used. India ink testing for visualization of the
capsule can detect ~103 CFU yeasts/mL in centrifugated cerebrospinal fluid (CSF) and has a sensitivity of ~60%–80% in
HIV-infected patients [3] and ~50% in non-HIV cryptococcal
meningitis. The change in quantitative CSF microscopy yeast
counts correlates poorly with changes in quantitative culture
and cannot be used as a surrogate marker [4].
Cryptococcal Antigen
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Cryptococcal antigen tests using latex agglutination, enzyme
immunoassay (EIA), or lateral flow assays (LFAs), have been
integrated into clinical practice and have >95% sensitivity
and specificity in CSF, serum, plasma, and whole blood [5, 6].
The CrAg LFA by IMMY (Norman, OK, USA) has the best
diagnostic performance of any current point-of-care assay
[3], with detection of both C. neoformans and C. gattii species but without the ability to distinguish between species.
Internationally, other non–Food and Drug Administration
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Early Fungicidal Activity

The slope of cryptococcal yeast clearance rate of serial CSF
quantitative cultures, termed early fungicidal activity (EFA)
[17, 18], is now a frequently used tool in clinical trials as
a direct marker of antifungal activity and a surrogate
marker for mortality [1, 19, 20]. In a 2020 meta-analysis of
738 cryptococcal meningitis participants from 3 sequential trials who received the same background induction
regimen of amphotericin B deoxycholate and fluconazole,
those with an EFA <0.20 log10 CFU/mL/d had an increased
18-week mortality compared with those with an EFA >0.20
(Figure 1) [19].
Furthermore, the association of EFA with mortality in HIVassociated cryptococcal meningitis is built on previous separate
prospective studies. Bicanic and colleagues used pooled data
from 4 trials in persons with HIV-associated cryptococcal meningitis undergoing induction with amphotericin B-based combination therapy or fluconazole monotherapy and found that a
slower rate of clearance was associated with 10-week mortality
[20]. Those who survived >10 weeks had mean EFAs of 0.41
log10 CFU/mL/d, vs 0.27 log10 CFU/mL/d in those who died. A
2016 systematic review of 27 trials including 2854 participants
(EFAs measured with different statistical techniques) also found
an association between mean EFA and 10-week survival [21],
although this analysis excluded inferior regimens with poor
EFAs, such as fluconazole monotherapy. While there are many
contributors to cryptococcal meningitis mortality, EFA is a validated surrogate marker for antifungal activity in humans and
for all-cause mortality, particularly when the EFA is <0.20 log10
CFU/mL/d. As Cryptococcus quantitative cultures take 3–7 days
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Figure 1. Association between EFA of CSF Cryptococcus yeast clearance rate
and mortality. Increased mortality was observed among those with an EFA <0.20
log10 CFU/mL CSF/d when receiving amphotericin B combination therapy in Uganda.
Above this EFA threshold could be a target for phase II trials. Reproduced with
permission from Pullen et al. [19]. Abbreviations: CFU, colony-forming units; CSF,
cerebrospinal fluid; EFA, early fungicidal activity.

to grow on standard fungal media [18], EFA is a delayed metric
that cannot be used in real time for clinical decision-making.
Quantitative CSF culture methodology has been published and
cross-validated [18].
Other Potential Biomarkers

Insufficient data exist for other surrogate markers for cryptococcal meningitis. Both CSF (1→3)-β-D-glucan (BDG) and
FilmArray polymerase chain reaction (PCR) testing (BioFire,
Salt Lake City, UT, USA) are potential diagnostic markers in
cryptococcosis, but both are suboptimal compared with CrAg
for diagnosis [22–25]. The rapid decay of CSF BDG and the
change in PCR cycle threshold (Ct) value for C. neoformans
DNA during antifungal therapy make these interesting potential surrogate biomarkers.
Summary and
Cryptococcosis

Recommendations

for

Surrogate

Biomarkers

in

CrAg is an established diagnostic biomarker that is more sensitive than culture. CrAg LFA is most sensitive. CrAg is preferred over BDG or PCR testing for diagnosis, but sequential
CSF CrAg titers should not be used for monitoring response
to therapy. The CSF clearance rate of Cryptococcus from serial
quantitative CSF cultures (EFA) is a direct marker of antifungal
activity and a surrogate biomarker of mortality and is now routinely used to evaluate novel antifungal strategies in cryptococcal meningitis clinical trials (Table 1).
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(FDA)–approved CrAg LFAs exist with substantially worse
diagnostic performance [7–9]. Serum or plasma CrAg LFAs
are >99.9% sensitive for detecting meningitis in HIV-infected
persons with meningitis, although if central nervous system
symptoms are present despite negative serum testing assessment of the CSF should be pursued [10, 11]. False-negative
tests are more common with CrAg latex agglutination and
in HIV-negative persons, where ~20% may have a falsenegative CrAg in serum with disseminated disease [3, 12].
False-negative CrAg LFAs are possible due to a prozone effect
at CrAg titers >1:1 million by serial dilution; however, a new
semiquantitative CrAg LFA has been developed that eliminates prozone [11]. The ability to provide a semiquantitative
CrAg titer provides prognostic information, as high titers
are correlated with high burden of disease and predict poor
prognosis [13, 14]. However, serial changes in CSF titers or
serum CrAg titers following treatment are not associated with
antifungal activity, change in CSF quantitative culture, or survival [15, 16]; thus, longitudinal CrAg titer change is not a
useful surrogate biomarker.

Table 1.

Summary of Fungal Biomarkers and Their Use for Diagnosis, Prognosis, or as Surrogate End Points in Clinical Trials
Diagnostic Biomarkers

Prognostic Biomarkers

Surrogate End Points for Treatment Trials

Cryptococcus

CrAg,
PCR

CrAg titer
Quantitative CSF culture
CSF BDG

Early fungicidal activity of serial quantitative CSF cultures is an established
end point

Candida

PCR,
T2Candida
BDG (nonspecific)

None validated

Possible: change in BDG, change in PCR
Ct value, or time to T2Candida negativity

Aspergillus

Blood galactomannan,
blood LFA for galactomannan, BDG,
PCR

Quantitative galactomannan value

Possible: change in blood galactomannan

Other molds

None

None

None

Blastomyces

Serum or urine antigen

Quantitative antigen possible

Possible: change in antigen or CRP

Coccidioides

Serology, PCR,

CF IgG titer

Possible: change in CF IgG titer

antigen
Histoplasma

Serum or urine antigen

Quantitative antigen

Possible: change in antigen titer

Paracoccidioides

IgG detection,
antigen

IgG titer

Possible: change in IgG titer

Sporothrix

PCR

None

None

Talaromyces

Serum or urine antigen
PCR

Quantitative blood culture

Early fungicidal activity based on serial
quantitative blood cultures

Abbreviations: BDG, 1,3-β-D-glucan; CF, complement fixation; CrAg, cryptococcal antigen; CRP, c-reactive protein; IgG, immunoglobulin G; LFA, lateral flow assay; PCR, polymerase chain
reaction.

INVASIVE CANDIDIASIS

Invasive candidiasis includes bloodstream infections by
Candida spp. (candidemia), which may be complicated by
end-organ infections from hematogenous dissemination, and
noncandidemic infections of organs or submucosal tissues.
Blood culture analysis is the gold standard and most common
approach for identifying candidemia. Noncandidemic invasive
candidiasis (deep-seated candidiasis) is typically diagnosed by
culture, staining, and/or histopathology of samples acquired by
biopsy or aspiration of involved tissue. Newer technologies and
commercially available methods have been developed for more
rapid diagnosis than the delay observed with cultures.
The average time to detection for culture-based systems
ranges from 14 to 38 hours and varies depending on the culture
conditions used (most Candida spp. grow more rapidly in aerobic than in anaerobic bottles) [26], the Candida species, and
the number of circulating yeast per mL of sample. Moreover,
limitations in the sensitivity, reliability, and timeliness of automated blood culture methods exist. The sensitivity of these assays decreases with the inocula (79% sensitivity with 1000 yeast
cells/bottle, 73% with 100 yeast cells/bottle, and 70% sensitivity
with 10 yeast cells/bottle). The mean detection time for C.
albicans is 20–30 hours depending on bottle type and inoculum
concentration [27]. Non-albicans species such as C. glabrata
may take considerably longer for growth (~80 hours).
Using culture-based diagnostic molecular assays, clinicians
are now able to decrease the time to organism identification and
improve antimicrobial agent selection and patient outcomes
[28]. For example, matrix-assisted laser desorption/ionization
mass spectroscopy (MALDI-TOF MS) is based on characteristic

mass spectral fingerprints unique to different microorganisms.
This technique requires growth of the organism on solid culture media before assessment. Other recently developed rapid
diagnostics performed directly on positive blood culture samples include Biofire Direct from Blood Culture, GenMark Yeast
ID from Blood Culture, Accelerate Pheno, and PNA Fish [29–
31]. The FilmArray blood culture identification panel, a multiplexed assay able to identify 24 different pathogens (BioFire
Diagnostics, Salt Lake City, UT, USA), provides results in ~1
hour with reported sensitivity of 96%–100% and specificity of
88%–100% [31, 32].
Limitations of culture techniques have spurred development
of culture-independent diagnostic tests for invasive candidiasis,
although uncertainty about test performance, costs, and utility
remains [33]. Traditional culture-based methods may be less
sensitive than newer methodologies and thus result in the erroneous interpretation that newer methodologies are less specific
than the traditional “gold standard” cultures despite detection
of more true-positive results (Table 2). Data are most robust
for 3 culture-independent diagnostic tests: (1→3)-β-D-glucan,
Candida polymerase chain reaction (PCR), and T2Candida assays of blood-based samples. Culture-independent diagnostic
test–guided patient management strategies have not been validated in clinical trials. We propose that patient populations
within the dark lines in Table 2 might be targeted for such future
trials to identify whether patients with “false-positive” cultureindependent diagnostic tests that are culture negative benefit
from antifungal therapy and thus are true positives. Below we
discuss how these assays can be rationally incorporated into patient care using current knowledge.
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Fungus

Abbreviations: BDG: 1,3-beta-D-glucan; ICU, intensive care unit; NPV, negative predictive value; PCR, Candida polymerase chain reaction; PPV, positive predictive value.

Culture-independent diagnostic test–guided patient management strategies have not been validated in clinical trials. We propose that patient populations with PPV >15% might be targeted for such trials to better identify the clinical benefit of response to
antifungal therapy. These “false positives” among high-risk patient populations may represent deep-seated invasive candidiasis that is negative by blood and other cultures.

ICU patient at increased risk for candidemia based on
clinical prediction score
~10%

Table 2 adapted from Clancy and Nguyen [34]. BDG sensitivity/specificity for diagnosing candidemia are taken from meta-analyses cited in the text. PCR and T2Candida sensitivity/specificity for diagnosing candidemia are taken from a meta-analysis and
DIRECT and DIRECT2 clinical trials [40, 42, 43]. In order to make rational use of culture-independent diagnostic tests, clinicians must be familiar with test performance and prevalence of various types of invasive candidiasis locally.
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1
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(70%/90%)
Beta-D-Glucan
(80%/80%)
Beta-D-Glucan
(60%/80%)

Performance Characteristics of Culture-Independent Diagnostic Tests for Candidemia as Compared With Culture as the Imperfect Reference Standard
Table 2.

BDG is a cell wall constituent of Candida and most pathogenic fungi. There is no conclusive evidence for the superiority of an assay by any particular manufacturer [34]. The
majority of the data are for the FDA-approved Fungitell assay
(Associates of Cape Cod, Cape Cod, MA, USA). Positive
BDG results do not identify Candida species or distinguish
between Candida and other fungi. Performance improves if
2 or more sequential samples are positive for BDG (>80 pg/
mL) [35]. False positives can occur with intravenous immunoglobulin, albumin, beta-lactam antibiotics, or bacterial infections [36].
In meta-analyses, serum BDG sensitivity and specificity for
invasive candidiasis (primarily candidemia) are ~75%–80% and
~60%–80%, respectively [37–40]. Performance varies greatly in
individual reports, with sensitivities ranging from 27% to 100%
and specificities ranging from 0% to 100% [41]. In studies of
deep-seated candidiasis (predominantly intra-abdominal candidiasis), sensitivities and specificities (interquartile range
[IQR]) were 65% (60%–77%) and 75% (64%–75%), respectively
(Table 3) [42–46]. A recent Cochrane report was unable to perform a meta-analysis or estimate BDG diagnostic accuracy for
invasive candidiasis due to heterogeneity in performance and
study design [41]. Serial BDG measurements are not generally
assessed in invasive candidiasis, although a negative slope (eg,
decline) in BDG levels has been correlated with successful treatment outcomes [47]; more data on longitudinal BDG change
are needed.
PCR

PCR offers potential advantages over BDG by specifically
targeting Candida spp. and allowing concurrent identification to the species level. Most PCR assays target C. albicans, C.
glabrata, C. parapsilosis complex, C. tropicalis, and C. krusei,
which account for >95% of cases of invasive candidiasis at most
centers. In a meta-analysis, PCR sensitivity was 95% and specificity was 92% for proven/probable invasive candidiasis (predominantly candidemia) [48]. Sensitivity and specificity for
proven/probable/possible invasive candidiasis were 73% and
95% respectively. Higher sensitivity was observed with whole
blood (as opposed to serum), and Candida- or fungal-specific
rather than broader multiplex assays. There was a trend toward lower specificity among patients colonized by Candida
[48]. Another meta-analysis investigated LightCycler SeptiFast
(Roche Diagnostics, Mannheim, Germany), a real-time multiplex PCR assay for the 5 most common Candida spp. and 20
other bacterial pathogens, among patients with presumed sepsis
[49]. In this study, the sensitivity and specificity for candidemia
were 61% and 99%, respectively. In studies of deep-seated candidiasis (predominantly intra-abdominal candidiasis), PCR
sensitivity and specificity vary from 25% to 91% and 33% to
97%, respectively [42–45].
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(1→3)-β-D-Glucan (BDG)

Table 3.

Anticipated Performance of BDG, PCR, and T2Candida in Various Populations at Risk for Intra-abdominal Candidiasis

BDG (65%/75%)
Prevalence, %

Representative Patient Populations

PPV, %

NPV, %

PCR, T2Candida
(45%/95%)
PPV, %

NPV, %

- Low- to moderate-risk peritoneal dialysis patient with peritonitis

12

97.6

37

97

10

- Patient with emergent surgery for intra-abdominal infection
- Patient with colonic perforation

22

95

56

94

20

- Patient with high-risk severe acute or necrotizing pancreatitis
- Patient with small bowel perforation
- Patient with emergent surgery for nosocomial intra-abdominal infection

39

90

74

87

30

- Patient who has undergone high-risk GI/hepatobiliary surgery
- Patient with a biliary leak
- Patient with a gastric/duodenal perforation

53

83

83

80

Table 3 adapted from Clancy and Nguyen [34]. BDG sensitivity/speciﬁcity values for diagnosing intra-abdominal candidiasis (the most common type of deep-seated candidiasis) are median
values from studies cited in the text. PCR and T2Candida sensitivity and speciﬁcity for diagnosis are representative of recently published studies, as cited in the text. In order to make rational
use of culture-independent diagnostic tests, clinicians must be familiar with test performance and prevalence of various types of invasive candidiasis locally.
PPVs and NPVs >15–30% and >85%, respectively, signify patients in whom nonculture testing may have the greatest clinical utility, assuming that antifungal treatment is justiﬁed at a
threshold likelihood of candidemia ≥15%–30%.
Abbreviations: BDG: 1,3-beta-D-glucan; GI, gastrointestinal tract; NPV, negative predictive value; PCR, Candida polymerase chain reaction; PPV, positive predictive value.

T2Candida

T2Candida (T2 Biosystems, Lexington, MA, USA) is an FDAapproved diagnostic for candidemia, which detects the 5 most
common Candida species within whole blood by an automated
process in which amplified DNA targets are detected by T2
magnetic resonance. In multicenter studies, T2Candida was
89%–91% sensitive and 98% specific for candidemia by targeted species [50, 51]. The mean time to Candida detection and
species identification was 4.4 ± 1.0 hours. Data for T2Candida
in clinical practice have shown this methodology as 65%–83%
sensitive and 93%–96% specific for candidemia [52, 53]. For
the diagnosis of deep-seated candidiasis (predominantly intraabdominal candidiasis), studies have found this system 33%–
45% sensitive and 93%–96% specific [53–55].
In small studies of intensive care unit patients at risk for invasive candidiasis, treatment strategies based on serum BDG
and T2Candida results were effective in shortening the time to
appropriate treatment of invasive candidiasis, safely reducing
unnecessary empiric antifungal use, and reducing costs [56–
60]. In a multicenter study from Spain of patients treated for
candidemia, positive T2Candida (but not BDG) within the first
5 days after a positive Candida blood culture was an independent
risk factor for either attributable mortality or development of
deep-seated candidiasis [61]. In a companion multicenter study,
positive T2Candida after institution of empiric therapy was an
independent predictor of death or proven candidiasis, whereas
BDG results were not predictive of mortality [62]. Clinical trials
of culture-independent diagnostic test–guided therapeutic
strategies are needed to validate impact on patient outcomes,
antifungal utilization, and health care costs. The results of the
CandiSep trial (NCT02734550, discussed below) will hopefully
increase our understanding of these tests and their impact on
antifungal prescribing.

Culture-independent diagnostic tests have the potential to be
useful as inclusion criteria for candidiasis trials. It is apparent
that culture alone detects only a subset of clinical disease.
Culture positivity should be an important a priori subgroup in
clinical trials, but limiting enrollment to culture-positive cases
leads to delays in enrollment and artificial populations not reflective of current clinical practice. The CandiSep prospective
randomized multicenter trial is evaluating whether the decision
to prescribe antifungals guided by (1,3)-β-D-glucan in comparison with standard of care shortens time to antifungal therapy
and reduces mortality. The results of this trial should inform inclusion criteria for future candidiasis trials. Most probably, culture positivity/negativity should be a standard a priori subgroup
analysis in future clinical trials, not restriction for an inclusion
criterion.
There is also a need to validate the clinical role of serial
changes of surrogate markers such as BDG or PCR Ct value,
or time to T2Candida negativity. With the exception of 1 BDG
study, associations are lacking between faster reduction in surrogate markers and clinical survival [47]. Validation of surrogate marker kinetics would allow for smaller phase II trials for
new agents or combination therapies. A starting point would be
to use existing cohorts with stored specimens to study longitudinal changes in biomarkers.
Summary and Recommendations for Surrogate Biomarkers in Candidiasis

Cultures remain the mainstay of candidiasis diagnostics yet
should not be the limiting inclusion criterion for invasive
candidiasis trials. Documented clearance of candidemia is a
marker of successful antifungal treatment. We recommend
using diagnostic molecular assays on positive cultures to accurately and rapidly identify organisms to species level. Cultureindependent diagnostic tests may be useful in selected clinical
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scenarios to initiate or de-escalate antifungal therapy. Positive
PCR or T2Candida testing in patients with risk factors for candidiasis warrants enrollment in clinical trials. Multiple possible biomarkers exist that could be used in phase II trials to
quantify antifungal activity, but these biomarkers have not been
validated.

Aspergillus spp. are ubiquitous in the environment and frequently inhaled into the airways [63]. Diagnosis of invasive
aspergillosis requires an appropriate host and compatible clinical syndrome when cultures from the airway return positive
to differentiate colonization from infection. Only culture of the
organism from a sterile site or demonstration of the organism
with hyphal invasion on histopathology is confirmatory of
proven disease [64]. The Aspergillus cell wall contains polysaccharides, BDG, chitin, and other components that may be utilized for detection in patient samples. Galactomannan and BDG
are the most well studied of these cell wall constituents.
Galactomannan Kinetics

The kinetic profile of serum galactomannan is complex and
depends on multiple factors including production and secretion, the fungal burden, the presence and function of neutrophils, the patient’s renal and hepatic function, and exposure
to antifungal agents with activity against Aspergillus spp.
Galactomannan presence in the circulation correlates with invasive growth of Aspergillus through the pulmonary capillaries,
and angio-invasion has been correlated with fungal burden and
galactomannan production [65, 66]. Together these findings
help explain the variable performance of serum galactomannan
in different patient populations (Table 4) [67]. For example,
serum galactomannan is detectable in patients with hematological malignancies and allogeneic hematopoietic stem cell
transplant recipients who have a higher burden of disease [68].
In contrast, the performance of serum galactomannan for the
diagnosis of invasive aspergillosis (IA) in solid organ transplant
patients, who typically have a lower burden of disease, is relatively poor [69, 70].
There has also been interest in determining if baseline
serum galactomannan values correlate with patient outcome
and whether the slope of serial galactomannan optical density

(1→3)-β-D-Glucan (BDG)
Table 4. Summary of Galactomannan Performance Characteristics in
Serum or Plasma Using a Cutoff ODI of 1.0
Population

Sensitivity, %

Specificity, %

Hematologic malignancy

58

95

Hematopoietic stem cell transplantation

65

65

Solid organ transplant

41

85

Table modified from Scott et al. [146].
Abbreviation: ODI, optical density index.
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The utility of BDG testing in the therapeutic monitoring of patients with IA has been poorly characterized. Pazos et al. first
evaluated BDG compared with galactomannan testing in a retrospective cohort of 40 high-risk neutropenic patients (5 proven,
3 probable, and 3 possible) [86]. The sensitivity, specificity, and
positive and negative predictive values of galactomannan and
BDG testing were almost identical; however, BDG was positive
earlier than galactomannan. In the evaluation of BDG testing as
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index readings correlates with survival. Multiple studies have
evaluated the role of baseline serum galactomannan as a predictor of treatment response and outcome of aspergillosis. In
a recent review of these studies, Mercier et al. found a correlation between serum galactomannan level and survival at 42
and 180 days of treatment among patients with positive serum
galactomannan (defined as cutoff >0.5 optical density index),
while serum galactomannan ≥2.0 optical density index at
baseline was associated with poor outcome [71]. In a recent
randomized controlled trial comparing anidulafungin in combination with voriconazole vs voriconazole alone, baseline
serum galactomannan was also an independent predictor of
6-week survival [72].
The role of measuring serial galactomannan in patients with
IA has been evaluated in several studies [68, 73–76]. Despite the
heterogenicity among these studies regarding outcome definition and galactomannan evaluation time points, the data suggest that a declining serum galactomannan value is a predictor
of survival, whereas persistently elevated serum galactomannan
correlates with death. One study reported that every 0.1-unit
increase in galactomannan optical density index from baseline
to week 2 corresponded to a 21% higher rate of an unsatisfactory clinical response [77].
Data on the effect of specific antifungal agents on serum
galactomannan kinetics are conflicting and remain a subject of
investigation. Some studies have shown a distinct kinetic profile
depending on the antifungal agent, while others have shown no
effect [78–80].
Galactomannan kinetics in bronchoalveolar lavage (BAL)
fluid are poorly understood and should be interpreted with caution, as this test is plagued with caveats including sampling error,
nonstandardized BAL fluid collection, and site of infection [81].
Based on the available data, current Infectious Diseases
Society of America guidelines recommend the use of serial
serum galactomannan only in patients with hematologic malignancies and hematopoietic stem cell transplant recipients who
have an elevated galactomannan at baseline to monitor disease
progression, therapeutic response, and prediction of patient
outcomes with IA [82].
The development of lateral flow assays has aided in the diagnosis of aspergillosis, although their role in sequential sampling
has not been defined thus far [83–85].

PCR

Availability of Aspergillus PCR testing in the United States remains limited; PCR is performed in reference laboratories only
(although Aspergillus PCR testing is commercially available in
Europe) [90]. The reported performance characteristics of PCR
vary given the different technologies, cycle thresholds for positivity, microbial targets, and study populations that have been
assessed [91]. A meta-analysis evaluating 25 studies found a
pooled sensitivity and specificity of 84% and 76%, respectively
[92]. In patients with 2 positive PCR results, the sensitivity was
found to be 64%, although specificity improved to 95% [93].
Few studies have evaluated sequential PCR testing for prognosis; however, quantitative PCR as copies/mL of serum at the
time of diagnosis has been found to be predictive of 90-day
mortality. The persistence of positivity or the development of
a negative test was predictive of 30- or 90-day mortality. Those
who became PCR negative between days 14 and 20 were all alive
at day 30, while those with PCR persistence exhibited 80% mortality at day 30 [94]. Time to PCR negativity with weekly sampling as an end point may be a future area to investigate.
Aspergillus fumigatus quantitative PCR from BAL has been
evaluated for the diagnosis and prognosis of both invasive and
noninvasive aspergillosis. In a 4-year retrospective study assessing 613 at-risk patients, the fungal burden (copies/mL) at
time of diagnosis was predictive of 90-day mortality with 23%
mortality for patients with <500 copies/mL, vs 68% for patients
with >500 copies/mL (P < .05) [95].
Summary and Recommendations for Surrogate Biomarkers in Aspergillosis

Galactomannan, BDG, and PCR are standard diagnostic tests
used in clinical practice, and some PCR assays have the advantage of also detecting mutations conveying antifungal drug

resistance. BDG has the least specificity and is insufficient as
a diagnostic biomarker for enrollment of patients into clinical
trials. For prognostic markers of response to antifungals, the
change in blood galactomannan values over time is a promising
serial surrogate marker. PCR negativity over time is also promising for use as a surrogate marker of patient outcomes.

OTHER MOLDS

Non-Aspergillus invasive mold infections caused by Mucorales,
Fusarium, Scedosporium spp., and others are increasingly encountered in an expanding population of severely immunosuppressed patients, accounting for 10%–25% of invasive
mold infections in autopsy studies [96], and are more common
among those receiving antifungal prophylaxis [97]. These
molds are characterized by resistance to multiple antifungals,
high potential for tissue invasion, and early dissemination with
poor outcomes [98]. Although host-related factors (activity of
underlying disease, comorbidities) are important for mortality
[99], early diagnosis can prevent the evolution of the infection
to multifocal or disseminated infection.
As symptoms, signs, and radiologic findings of nonAspergillus invasive mold infections lack sensitivity and specificity, diagnosis is often delayed, resulting in delayed treatment
and poor outcomes. The importance of early effective therapy in
these mold infections is poorly understood, with the exception
of mucormycosis, for which early therapy with anti-Mucorales
agents has been shown to improve survival [100]. Conventional
diagnostic confirmation requires invasive procedures such as
biopsy or BAL, which are often not feasible in ill patients with
severe pancytopenia [101].
The performance of commercially available biomarkers for
these pathogens is also problematic. In addition to Aspergillus
species, galactomannan is produced by several non-Aspergillus
molds [102], particularly other hyalohyphomycetes such as
Fusarium spp. [103]. Galactomannan is negative in patients
with mucormycosis. Most non-Aspergillus invasive mold infections in high-risk patients are breakthrough infections in those
already receiving anti-Aspergillus antifungals [104]. Finally,
while BDG cannot identify organisms to the species level, a
positive BDG can suggest the presence of molds. More data are
needed on longitudinally prognostic data in non-Aspergillus
molds [105, 106].
The development of culture-independent biomarkers for the
early diagnosis of these important organisms is critically important. The field of PCR-based diagnostics in serum and/or BAL
that target Mucorales are the most developed. Several small
studies show promising high sensitivity and specificity that
could lead to earlier diagnosis, although detailed comparisons
to standard microbiologic methods are lacking [107]. In a small
study using targeted screening for the detection of circulating
Mucorales DNA by real-time quantitative PCR in seriously ill
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a prognostic tool, plasma concentrations showed a consistent
increase before clinical and microbiologic evidence of disease but decreased and became negative following a response
to antifungal treatment. In contrast, those nonresponsive to
antifungal therapy showed a persistence of BDG positivity.
Others have similarly observed a decrease in BDG values following a response to therapy [87].
Others have compared BDG and galactomannan directly in
the prognosis of IA. In a study of 51 evaluable patients, there
was an association between changes from baseline to week 12
when BDG and galactomannan were summed; however, the use
of BDG alone was not statistically significant. Others have described similar findings, with most patients having BDG values
through 6–12 weeks persistently >80 pg/mL, and with the trajectory not predictive of 6- or 12-week outcomes [88]. BDG
kinetics are slow and may require >4–6 weeks after treatment
initiation to appreciably change [75]. These limitations, and the
intrapatient variability of BDG testing, prompt the authors to
not recommend serial BDG [89].

Summary and Recommendations for Surrogate Biomarkers in
Non-Aspergillus Molds

Diagnostics for non-Aspergillus molds require further development, and specific biomarkers for these organisms would be
helpful in disease management. Insufficient data exist on the
utility of using any surrogate end points in clinical trials.
BLASTOMYCOSIS

End points for successful outcomes of treatment in blastomycosis classically have been clinical improvement together
with resolution of skin lesions or radiologic findings. A
standard assay for the diagnosis of probable blastomycosis
is a Blastomyces antigen, which measures the cell wall polysaccharide (galactomannan) of Blastomyces dermatitidis
(Mira Vista Laboratories, Indianapolis, IN, USA) in urine,
serum, or body fluids (Table 5) [64, 110–112]. However,
longitudinal antigen measurement to follow the course of
infection has been infrequently reported [113–115]. Three
children with blastomycosis had serial urine antigen tests
performed during treatment [113]. Fall in antigen levels to
undetectable occurred in 2 who were cured, but the third
did not respond to antifungal therapy and antigen positivity
persisted [114].
A more systematic approach to the use of Blastomyces antigen detection to follow the disease course included 19 patients
with serial urine antigen tests performed [115]. Antigen levels
declined, but time to a negative result varied greatly among 16
patients who were successfully treated. In 3 patients who failed
therapy, urine antigen levels increased.
Summary and Recommendations for Surrogate Biomarkers in
Blastomycosis

There are insufficient data to recommend biomarkers for the
prognosis of blastomycosis or as surrogate end points in clinical trials. Longitudinal change in serum Blastomyces antigen
requires further investigation. Surrogate markers for prognosis
of the more severe disease manifestations of acute respiratory
distress syndrome in blastomycosis are needed.
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COCCIDIOIDOMYCOSIS

Past studies of coccidioidomycosis have used combined clinical score, radiologic results, and serologic results to determine
a composite score for clinical severity [116]. Serologic testing
may be performed using a number of methodologies (Figure 2).
EIA appears to have the highest sensitivity, although it is prone
to false positives and results should be confirmed with immunodiffusion testing [117, 118]. A newly developed lateral flow
assay exhibited poor sensitivity (31%) [119]. Coccidioidal complement fixation (CF) testing for quantitative detection of immunoglobulin G has prognostic utility in both serum and CSF
samples (Table 5) [120]. Serial serum samples correlate with
patient symptoms and are useful for monitoring the course of
therapy. It is imperative to recognize the differences in types of
coccidioidal infection and the impact this plays in the kinetics
of serology in determining a response to therapy, as serologic
decline is slower in those with chronic pulmonary or disseminated coccidioidomycosis compared with those with primary
pulmonary coccidioidomycosis [120, 121].
Serial serologic testing of CSF in cases of coccidioidal meningitis has shown a correlation with other CSF indices, including
cell count, protein, and glucose; however, both serology and routine CSF parameters respond more slowly than clinical signs and
symptoms of disease, and clinical decisions should be based on
symptoms, CSF parameters, and serology results together [122].
A real-time PCR assay has been developed for detection of
Coccidioides in lower respiratory specimens [123]. Coccidioidal
antigen testing is also commercially available and may be useful
in highly immunocompromised patients who are serologically
negative [124]. BDG has been found to have 44% sensitivity and
91% specificity in coccidioidomycosis [125]. Serial antigen and
BDG testing of the serum, urine, or CSF are not routinely performed due to a lack of data supporting this approach.
Summary and Recommendations for Surrogate Biomarkers in
Coccidioidomycosis

Serologic testing is useful for the diagnosis of coccidioidomycosis, and EIA results should be confirmed by immunodiffusion. Longitudinal assessment using CF serology is useful to
monitor the response to antifungal therapy. However, insufficient data exist on their utility as surrogate end points for use
in clinical trials.
HISTOPLASMOSIS

Historically, the first prognostic marker for histoplasmosis was
duration of positive blood cultures in patients with HIV who
were receiving antifungal therapy [126]. In studies performed
during the early AIDS era, recurrence of disease was associated
with positive or persistently positive blood cultures [127–130].
Blood cultures are infrequently positive in patients who are
HIV-negative [131], and the time to positivity (average of >2
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burn patients to identify invasive wound mucormycosis, a mortality benefit was suggested [108]. Other innovative approaches
are needed and may involve serologic assessment, detection of
volatile organic compounds or other metabolomics, and validation of antigen testing, immunohistochemistry, PCR, and
metagenomic sequencing in selected cases of non-Aspergillus
invasive mold infections.
The best example of diagnostic and prognostic use to date
was in the Exserohilum rostratum meningitis outbreak, where
PCR and BDG were utilized for CSF diagnosis and CSF BDG
levels could be used to monitor response to antifungal therapy
[106, 109]. More data are needed on response to therapy for
other molds.

Table 5.

Comparison of Diagnostic Tests Utilized in the Diagnosis of Endemic Mycoses

Diagnostic Test

Sensitivity,
%

Specificity, %

Strengths

Limitations

Histoplasma
15–84

Inadequate data but presumed
~100 in most studies based
on reference standard definitions

More useful in SPH and CPH

Slow growth, 4–8 wk
Less useful in APH

Cytopathologic examination
[8, 16, 17, 19, 20]

9–50

Inadequate data available,
generally considered fairly
specific but presence of
Histoplasma in tissue may
indicate past rather than
current infection; may also
be misidentified

Rapid results (hours)
More likely to be positive in SPH
and CPH

Sensitivity and specificity vary
based on pathologist experience
Requires invasive procedures
Less useful in pulmonary disease
without dissemination

Serum antigen [13, 19,
21–23]

30–87

98

Fast results (days)
Improving availability
Most useful in APH

Cross-reacts with other fungi
Less useful in SPH and CPH

Urine antigen [8, 13, 15, 17,
19, 21, 24]

40–95

95–99

Fast results (days)
Improving availability
Most useful in APH

Cross-reacts with other fungi
Less useful in SPH and CPH

Antibody [8–10, 13, 14]

40–95

91

Fast results (days)
More useful in SPH and CPH

Take 4–8 wk to develop antibodies
Can be negative in immunocompromised individuals
Cross-reacts with other endemic
mycoses

66–90

Inadequate data but presumed
~100 in most studies based
on reference standard definitions

Gold standard for diagnosis

Slow growth, up to 5 wk

Commercial DNA (AccuProbe;
GenProbe Inc., San Diego, CA,
USA) testing can provide rapid
results once there is sufficient
growth

Diagnostic yield varies based
on site

Rapid results (hours)

Sensitivity varies based on pathologist experience

Blastomyces
Sputum/BAL culture [1,
25–28]

Histologic or cytopathologic
examination [26–30]

38–93

Inadequate data, generally considered highly specific, but
misidentification may occur;

DNA probe can cross-react with
Paracoccidioides

Atypical forms of B. dermatitidis
may require special stains

presence of Blastomyces in
tissue typically indicates
active
infection
Potassium hydroxide smear
[25, 27, 28]

48–90

No data available, generally
considered highly specific but
false positives possible

Rapid results

Varied sensitivity

Serum EIA antigen [1, 25,
29, 31, 32]

36–82

99 compared with nonfungal
infections or healthy controls
but 95.6% cross-reactivity
with 90 cases of histoplasmosis

EDTA heat treatment improves
sensitivity

Cross-reacts with other fungi
Only available at reference labs

Urine EIA antigen [1, 27, 29,
31–33]

76–93

79–99

Can be utilized to monitor response to treatment

Cross-reacts with other fungi
Only available at reference labs

Antibody testing via complement fixation [28,
34, 35]

16–77

30–100

Fast results (days)

Difficult to perform, variable performance

Antibody testing via immunodiffusion [28, 29,
34, 36]

32–80

100 in 1 study, possibility for
cross-reaction remains

Fast results (days)

Can be negative in immunocompromised patients

Antibody testing via EIA
(BAD-1) [33, 36]

88

94–99

Low rate of cross-reactivity
Increased sensitivity when combined with antigen testing

May be negative early in infection
and in immunocompromised
individuals
Not commercially available

56–60

100

Grows well on most media in
2–7 d, specificity

Biohazard to laboratory staff

Coccidioides
Culture [37]

Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases • OFID • 9

Downloaded from https://academic.oup.com/ofid/article/9/6/ofac112/6542571 by Washington University in St. Louis user on 28 December 2022

Sputum/BAL culture [10, 11,
15, 16, 19, 20]

Table 5.

Continued

Specificity, %

Strengths

Limitations

Histologic or cytopathologic
examination [37, 38]

22–55

99.6

Rapid results

Requires invasive procedures
Endospores may be mistaken for
Histoplasma, Blastomyces, or
Cryptococcus

Serum antigen [39, 40]

28–73

90–100

Most useful in immunocompromised and severe disease

Cross-reactivity with Histoplasma
and Blastomyces

Urine antigen [39, 41, 42]

50–71

90–98

Most useful in immunocompromised and severe disease

Cross-reactivity with Histoplasma
and Blastomyces

Immunodiffusion antibody
assays (IDTP and IDCF)
[42, 43]

60.2–71

98.8

Quantitative titers correlated to
disease severity and can monitor treatment response
Commonly used as
confirmatory test

Only available at reference labs
Less useful in immunosuppressed
patients
May be negative early in disease

EIA antibody assay [40,
43–49]

83–100

75–98.5

Commercially available
Faster results

Needs confirmatory testing
Not quantitative
IgM cross-reacts with other mycoses
Less useful in immunosuppressed
patients
May be negative early in disease

Skin testing (Spherusol) [50]

>98

>98 for prior exposure

Negative test may mean
Coccidioides infection less likely

Only indicates prior exposure, unclear role in active infection

Culture [51]

25–44

100

Specificity

Requires 2–4 wk to grow, infrequently used

Histologic or cytopathologic
examination [52, 53]

55–97

Presumed highly specific but
inadequate data and
misclassification possible

Gold standard test, results in
hours–days

Requires invasive procedures

Double immunodiffusion
antibody assay [52–56]

80–90

>90, inadequate data

Most commonly utilized
antibody test

Cross-reactivity with other fungi
Less useful for diagnosis of P.
lutzii

ELISA antibody assay [52,
57, 58]

95.7

85–100

Simple to perform
Fast results
Antibodies can be detected at
low concentrations

Cross-reacts with other fungi
Requires confirmatory DID Ab
Less useful for diagnosis of P.
lutzii

Latex agglutination antibody
testing [56]

69.5–84.3

81.1

Simple to perform

Poor reproducibility
Limited availability
Less useful for diagnosis of P.
lutzii

Blood culture [59–62]

72.8–83

100

Gold standard
Highly specific
May culture other sterile sites
as well

Takes up to 4 wk to grow
More likely to be positive in late
stages of infection

Sputum culture [59, 60, 63]

11–34

Inadequate data, presumed
highly specific

Highly specific

Takes up to 4 wk to grow

Inadequate data, presumed
highly specific

High specificity, for some tissues
high sensitivity

Paracoccidioides

Talaromyces

Culture from other tissues
[59–61]
-Skin

6–90

-Yield only accurate if the area is
involved, slow growth

-Bone marrow

17–100

-Painful, variable sensitivity–invasive, variable sensitivity

-Lymph node

34–100

-Invasive, small numbers studied

-Cerebrospinal fluid

15

-Invasive, small numbers studied

-Palatal/pharynx papule

10

-Painful, small numbers studied

-Liver

5

-Invasive, small numbers studied

-Pleural fluid

5

Cytology [63]

46

Inadequate data, presumed
highly specific, but
misidentification may occur

Specificity

Small numbers in studies, requires invasive procedures in
most cases

Lateral flow
immunochromatographic
antigen assay (4D1) [64]

87.9

100

Rapid results
Easy to perform

Not commercially available
Urine testing only
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-Invasive, small numbers studied
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Sensitivity,
%

Diagnostic Test

Table 5.

Continued

Specificity, %

Strengths

Limitations

Antigen via EIA (Mp1p antigen) [62]

86.3

98.1

Rapid results
Sensitivity further increased
when both urine and serum
tested

Not commercially available

Mab 4D1 inhibitory ELISA
antigen assay [65]

100

100

Low cross-reactivity
Can be utilized on serum

Only tested on small sample size
(n = 45), results need confirmation

Adapted from Poplin et al. [159].
Abbreviations: Ab, antibody; APH, acute pulmonary histoplasmosis, CPH, subacute pulmonary histoplasmosis; DID, double immunodiffusion; EIA, enzyme immunoassay; ELISA, enzymelinked immunosorbent assay; IDCF, immunodiffusion complement fixation; IDTP, immunodiffusion tube precipitin; SPH, subacute pulmonary histoplasmosis.

weeks) limits their applicability during the care of patients in
clinical practice or during the conduct of clinical trials.
The most widely used surrogate marker for histoplasmosis
diagnosis is the Histoplasma polysaccharide galactomannan
antigen, which can be detected in urine or serum (Figure 3)
[132–135]. Histoplasma antigen assays have been developed by
MiraVista (Indianapolis, IN, USA) and IMMY (Norman, OK,
USA), among others. Only 1 study has compared the MiraVista
lateral flow assay and IMMY galactomannan enzyme immunoassay on 391 urine samples (n = 104 proven disseminated
histoplasmosis) in persons with HIV; it reported similar sensitivity (90%–91%) and specificity (91%–92%) (Table 5) [136].
The Histoplasma antigen decreases during successful antifungal
therapy [137, 138]. Antigenemia decreases more rapidly than
antigenuria in successfully treated patients with HIV, although
failure of antigen to decline during the first 2 weeks of therapy
does not predict treatment failure [133]. Among those with
clinical relapse, 86% had a significant increase in their longitudinal antigen levels [139].
Antibody testing is most useful for nonimmunosuppressed
patients with chronic or subacute pulmonary histoplasmosis

and may be negative in those with severe immunosuppression
(Figure 4). Negative testing should be repeated in 1–2 months
if suspicion is high. While antibodies do appear to decay following acute disease, there is no evidence that changes, or lack
thereof, in antibody titers predict mortality, treatment success,
or recurrence [137].
Summary and Recommendations for Surrogate Biomarkers in
Histoplasmosis

Urine Histoplasma antigen is well studied in patients with HIV
and is useful in diagnosis, patient management, and as a potential end point in clinical trials. In other populations, further
studies should be performed to define the usefulness of longitudinal antigen testing to determine prognosis.
PARACOCCIDIOIDOMYCOSIS

Serologic testing is frequently used in the diagnosis of
paracoccidioidomycosis and is highly specific (>95%) and sensitive (~80%) [140–142]. Numerous methodologies have been
investigated, including in-house assays, although a commercial immunodiffusion test is now available. A previous study

Clinical suspicion for
coccidioidomycosis

Serologic testing

LFA

EIA for
IgM/IgG
Positive
Probable coccidioidomycosis,
obtain complement fixation
titers to further assess

Negative

Positive

Negative

Probable coccidioidomycosis,
obtain complement fixation
titers to further assess
Consider alternative
diagnosis
OR
If concern remains, consider
repeat testing; or if
immunocompromised
consider antigen testing

LFA with low sensitivity,
consider repeating test with
alternative methodology

ID/CF
Positive

Negative

Probable
coccidioidomycosis
Consider alternative
diagnosis
OR
If concern remains, consider
repeat testing; or if
immunocompromised
consider antigen testing

Figure 2. Serologic testing in coccidioidomycosis. Abbreviations: EIA, enzyme immunoassay; IgG, immunoglobulin G; IgM, immunoglobulin M; LFA, lateral flow assay.
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Sensitivity,
%

Diagnostic Test

In a cohort of 23 patients followed for 8–12 months, antigen decreased during therapy with itraconazole and was undetectable
in all patients after 12 months of treatment [144]. Unfortunately,
this test is not commercially available.

Both
80%
(90/113)

Urine
3.5%
(4/113)

Serologic testing is useful for the diagnosis of
paracoccidioidomycosis and is useful to monitor the response
to antifungal therapy. However, insufficient data exist on serology as a surrogate end point for use in clinical trials.
SPOROTRICHOSIS

Figure 3. Diagnostic overlap in histoplasmosis antigen by specimen type. Data
are drawn from 113 total cases consisting of 56 disseminated histoplasmosis, 32
acute pulmonary histoplasmosis, 1 subacute pulmonary histoplasmosis, 6 chronic
pulmonary histoplasmosis, 1 granulomatous mediastinitis, 15 unknown, and 5
cases not detected in either specimen type [132–135]. Antigen sensitivity is higher
in disseminated histoplasmosis and/or in immunocompromised hosts than in acute
pulmonary histoplasmosis or in immunocompetent hosts.

Disseminated
disease

Pulmonary disease

Immune
disease

Duration of pulmonary disease

Immunocompromised

Histoplasma antibody

Histoplasma antigen burden

found longitudinal serologic assessment useful to monitor response to therapy [143]. This analysis of 43 patients with acute
or chronic paracoccidioidomycosis found a decline in antibody
levels using counter-immuno-electrophoresis, complement fixation, or enzyme-linked immunosorbent assay testing during
a follow-up period of 2 years coincident with patient clinical
improvement. Clearance of antibody occurred only in those
with single-site disease over 12 months of follow-up. Patients
with relapsed disease had an increase in serum titer levels, exhibiting the utility of serial monitoring. However, serology antibody titer in some cases may increase following initiation of
antifungal therapy, thereby complicating using serology as a
practical surrogate marker.
Antigen testing has also been examined as an adjunct to the
diagnosis of paracoccidioidomycosis (Table 5) [142, 144, 145].

Immune function
Immunocompetent

Dysregulated

Figure 4. Conceptual framework for histoplasmosis. The relationship between
host immunosuppression, type of disease, and antigen or antibody titers.
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Serologic testing is infrequently used in the diagnosis of
sporotrichosis despite the availability of a commercial assay.
A latex agglutination assay was previously evaluated to assist with the diagnosis of meningeal sporotrichosis [146];
however, this assay is no longer available, and serologic
testing is generally not helpful in other forms of sporotrichosis. Newer assays have been studied and exhibit reasonable sensitivity and specificity but are limited by availability
[146–148]. The utility of serology to assess a response to
antifungal therapy variably correlates with clinical response,
and this test is not routinely recommended or commercially
available [149, 150].
Summary and Recommendations for Surrogate Biomarkers in
Sporotrichosis

Several assays are in development that may offer promise in the
diagnosis of sporotrichosis, and they may be useful biomarkers
during future clinical trials following validation. Currently,
there are no biomarkers that can be used as a surrogate end
point in clinical trials.
TALAROMYCOSIS

The current culture-based diagnosis for talaromycosis is
suboptimal due to prolonged incubation (3–14 days) and
low yield during the early stage of infection (Table 5) [151].
Several real-time PCR assays performed in blood have
shown promising diagnostic performance in small clinical studies [152, 153]. An antigen detection EIA targeting
the Talaromyces marneffei–specific cell wall mannoprotein
Mp1p is highly sensitive (86%) and specific (98%) in comparison with blood cultures (73% and 86%, respectively)
[151, 154, 155]. A commercial Mp1p EIA was approved in
China in 2019, and an Mp1p LFA is being developed by
IMMY (Norman, OK, USA).
Assessment of therapeutic response in talaromycosis has
historically been based on a composite clinical and microbiological end point of resolution of fever, skin lesions, and/
or fungemia [156, 157]. Mp1p concentrations have been

Downloaded from https://academic.oup.com/ofid/article/9/6/ofac112/6542571 by Washington University in St. Louis user on 28 December 2022

Serum
12%
(14/113)

Summary and Recommendations for Surrogate Biomarkers in
Paracoccidioidomycosis

Summary and Recommendations for Surrogate Biomarkers in
Talaromycosis

Culture remains the mainstay of diagnosis for talaromycosis.
Antigen testing may be useful in future clinical trials following
validation, but currently cannot be recommended as a surrogate end point in clinical trials. The longitudinal change in
quantitative blood CFUs has been found useful to quantify the
EFA in a recent clinical trial and should be a standard metric in
future clinical trials.
FUTURE DIRECTIONS

There have been significant advances utilizing surrogate
markers of fungal infections to predict patient outcomes. These
tests have been a welcome advance; however, numerous challenges remain. The development of affordable, readily available, and rapid in-house diagnostic tests is critically important.
Cryptococcosis and talaromycosis are the only fungal infections
with established surrogate end points, and further investigation of surrogate markers for other invasive fungal infections
is urgently needed to aid in both diagnosis and prognosis. The
burden of invasive candidiasis and aspergillosis mandates urgent attention to these diseases. Finally, a concerted effort to
evaluate promising diagnostic tests as surrogate markers to
measure response to therapy through the conduct of testing
well-documented clinical samples is essential to move this field
forward and to optimize patient care.
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